Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

32.85 -0.83 (-2.46%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Volume	617,342
Open	33.91
Bid (Size)	32.51 (100)
Ask (Size)	33.56 (100)
Prev. Close	33.68
Today's Range	32.46 - 34.34
52wk Range	5.350 - 38.69
Shares Outstanding	44,188,534
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Performance

YTD	+6.3%	+6.3%
1 Month	+7.8%	+7.8%
3 Month	+9.9%	+9.9%
6 Month	+172.8%	+172.8%
1 Year	+266.6%	+266.6%

More News

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

Via The Motley Fool

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

December 09, 2025

Via Chartmill

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

December 01, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

November 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

November 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

6 Analysts Have This To Say About Stoke Therapeutics ↗

November 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 04, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Examining the Future: Stoke Therapeutics's Earnings Outlook ↗

November 03, 2025

Via Benzinga

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

October 30, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

October 20, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗

October 10, 2025

Via Benzinga

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 09, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 09, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

October 06, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

September 02, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?

Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?

Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?

The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market

What is the current price of Stoke Therapeutics, Inc. - Common Stock?

The current price of Stoke Therapeutics, Inc. - Common Stock is 32.85

When was Stoke Therapeutics, Inc. - Common Stock last traded?

The last trade of Stoke Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?

The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.45B

How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?

Stoke Therapeutics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.